AUSTIN, Texas--(BUSINESS WIRE)--Asuragen, Inc., a molecular diagnostic company using genomics to drive better patient management, announced today that it had received a clinical laboratory permit from the state of New York to offer Xpansion Interpreter, its reflex test for fragile X carriers and miRInform Thyroid for use in the management of patients with thyroid nodules. With this approval, Asuragen can now offer its CAP-certified CLIA laboratory Xpansion Interpreter and miRInform Thyroid Tests in all 50 states.
Help employers find you! Check out all the jobs and post your resume.
